Finland-based Aplagon Oy has closed a EUR 4.8 million (approximately USD 5.6 million) financing round to fund a new Phase II clinical program for APAC, Aplagon's investigational heparin proteoglycan mimetic with antiplatelet, anticoagulant and anti-inflammatory activity. The trial will assess APAC in arteriovenous fistula (AVF) maturation failure in end stage kidney disease — a condition affecting a substantial proportion of patients requiring hemodialysis and for which no targeted pharmacological therapies are approved.
The financing was led by existing investors Fåhraeus Startup and Growth AB (FSG) and the European Innovation Council (EIC) Fund, with continued participation from Finnish investors including the Jenny and Antti Wihuri Foundation, Innovestor, and the Gösta Serlachius Fine Arts Foundation. The company said it has recently filed a Clinical Trial Authorization (CTA) with the European Medicines Agency for the AVF programme. To date, Aplagon has raised over EUR 20 million through equity and non-dilutive funding.
Proceeds from the round will support the initiation and execution of the Phase II AVF maturation failure study in Europe. The AVF indication represents a meaningful expansion of Aplagon's clinical strategy beyond its lead Phase IIa programme in peripheral arterial occlusive disease (PAOD) leading to chronic limb threatening ischemia (CLTI), for which the company dosed its first patient in the HEALING trial earlier this year.
Aplagon's sole clinical asset is APAC, a heparin proteoglycan mimetic designed to simultaneously inhibit platelet activation and thrombin generation — the two principal drivers of arterial thrombosis — while also suppressing local inflammation at vascular injury sites. By mimicking naturally occurring mast cell-derived heparin proteoglycans, APAC localises to sites of vascular damage, delivering targeted antithrombotic and anti-inflammatory activity in situ. It can be administered either locally or by intravenous infusion, supporting use across multiple in-hospital settings. A peer-reviewed publication in Arteriosclerosis, Thrombosis, and Vascular Biology, published in June 2026, summarised the preclinical and clinical evidence supporting APAC's mechanism and provided scientific validation for the asset's differentiated approach relative to conventional antithrombotics.
The mechanism is relevant to AVF maturation failure because the surgical creation of an arteriovenous fistula — required to establish vascular access for haemodialysis — triggers acute platelet activation and vascular inflammation that frequently impairs the fistula's ability to mature for long-term dialysis use. Approximately 130,000 new AVFs are created annually in the US alone, and around half fail to mature adequately, leading to repeat procedures, hospitalisation, and increased healthcare costs. Aplagon believes APAC's localised vascular protective effects could meaningfully improve maturation outcomes by reducing platelet activation and vascular injury immediately following surgery.